Clinical trials: COVID-19 Vaccines
COVID-19
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
- Trial name
- NCT06255626
- Testing
- CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- Where
- 2 sites in France
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months…
- Trial name
- NCT05396573
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
COVID-19 Respiratory Infection
Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers
Group 1 (BBV154): In this group, 3000 participants will be recruited, randomized in 1:1:1 ratio receive 3 consecutive lots (Lot 1: 1000, Lot 2: 1000, Lot 3: 1000) of the BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via…
- Trial name
- Nasal154PH3 (NCT05522335)
- Testing
- BBV154(Intranasal) & covaxin
- Where
- 14 sites in India
- Volunteers
- 3,160 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Chronic Lymphocytic Leukemia, COVID-19
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies.
- Trial name
- PACE-CLL (NCT05465876)
- Testing
- EVUSHELD
- Where
- Canada
- Sponsor
- Sunnybrook Health Sciences Centre
COVID-19
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus.
- Trial name
- BRILIFE002 (NCT04990466)
- Testing
- IIBR-100, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroRx, Inc.
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Covid19
Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on…
- Trial name
- NCT04608305
- Testing
- IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime)
- Where
- 8 sites in Israel
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Israel Institute for Biological Research (IIBR)
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
Social Acceptance, Social Anxiety
Social Acceptability of COVID-19 Vaccines in Pakistan
Social settings of Pakistan is unique in the sense that it is composed of multilingual, multicultural and different ethnicities. Also their believes and faiths are so unpredictable.
- Trial name
- NCT04727372
- Testing
- Questionnaire
- Where
- 4 sites in Pakistan
- Volunteers
- 986 people
- Sponsor
- Islamia University of Bahawalpur
Covid19
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full…
- Trial name
- VAX-TRES (NCT04930770)
- Testing
- MRNA-1273
- Sponsor
- Maria Joyera Rodríguez
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
SARS-CoV-2 Infection
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.
- Trial name
- NCT05364242
- Testing
- VLA2001
- Where
- 4 sites in Netherlands, New Zealand
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
COVID-19
Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults
A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed…
- Trial name
- NCT06441968
- Testing
- MPV/S-2P
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
Diabetic Complication, Covid19 Virus Infection
Suspicion of Hypoglycemic Effect of mRNA Based Covid-19 Vaccines (Polyethylene Glycol) Will Happen , Observational Study on Diabetic Patients at Saudia Arabia
vaccines for covid-19 are gold strategy and great achievement at this century for protection against complications of covid-19 , development of many vaccines with different technology represent a big challenge for this disease so…
- Conditions
- Diabetic Complication, Covid19 Virus Infection, Hypoglycemia, Polyethylene Glycol Adverse Reaction
- Trial name
- NCT05087225
- Testing
- polyethelyene glycol
- Where
- Saudi Arabia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
Myocardial Injury, Vaccine Adverse Reaction
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
- Conditions
- Myocardial Injury, Vaccine Adverse Reaction, COVID-19
- Trial name
- NCT05308680
- Testing
- BNT162b2
- Where
- Israel
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
SARS-CoV2 Infection, Covid19
Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
The PLAN-V Study is an Ontario-based prospective, longitudinal study that will consist of extensive biosampling and detailed data collection from pregnant women/individuals, who have received the COVID-19 vaccine during their…
- Conditions
- SARS-CoV2 Infection, Covid19, Vaccine Reaction, Pregnancy Related
- Trial name
- PLAN-V (NCT05115617)
- Where
- 7 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
COVID-19 (Coronavirus Disease 2019)
Understanding COVID-19 Vaccine Immunity in Tissue and Blood
The purpose of this study is to understand the effects of COVID-19 vaccines on the immune system and how the COVID-19 vaccines provide protection and induce long term memory.
- Trial name
- NCT05682625
- Testing
- No intervention
- Where
- United States
- Sponsor
- Stanford University
Covid19, Kidney Transplantation
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general…
- Trial name
- COVATRANS (NCT04828460)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive…
- Trial name
- NCT04852289
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute on Aging (NIA)